SCHEMBL945801

SCHEMBL945801

CC(C)(C)OC(=O)CCCCc1cccc(COS(C)(=O)=O)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
HDAC8 Q9BY41 1/20 0.34
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
NQO2 P16083 1/20 0.32
PTGER2 P43116 1/20 0.31
VSIR Q9H7M9 1/20 0.31
TBXA2R P21731 1/20 0.31
TBXAS1 P24557 1/20 0.31
EPHX2 P34913 1/20 0.31
KMT2A Q03164 1/20 0.31
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CB P42338 1/20 0.30
PIK3CG P48736 1/20 0.30
P2RY12 Q9H244 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948367 0.82 KCNH2 (0.41) KCNH2NPSR1HDAC8CYP4F2CYP4A11
SCHEMBL412330 0.77 KDM4E (0.41) CYP1A2CYP3A4CYP2D6NPSR1KMT2A
SCHEMBL25321212 0.76 KCNH2 (0.44) CYP1A2CYP3A4CYP2D6KCNH2NPSR1
SCHEMBL19623088 0.75 CES1 (0.43) CYP1A2CYP3A4KCNH2HDAC8
SCHEMBL946119 0.74 NPSR1 (0.41) KCNH2NPSR1NQO2VSIRKMT2A
SCHEMBL1740788 0.73 KDM4E (0.38) CYP1A2CYP3A4CYP2D6NPSR1
SCHEMBL1419785 0.73 CYP1A2 (0.35) CYP1A2CYP3A4CYP2D6NQO2PTGER2
SCHEMBL465906 0.73 CCR2 (0.43) NQO2PTGER2KMT2A
SCHEMBL946003 0.72 NPSR1 (0.42) KCNH2NPSR1CYP4F2CYP4A11NQO2
SCHEMBL17247586 0.72 CYP1A2 (0.40) CYP1A2CYP3A4CYP2D6KCNH2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989446-B2 4-amino 5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 US disclosed
US-7989446-B2 4-amino 5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 US disclosed
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. 2011-01-13 US disclosed
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. 2011-01-13 US disclosed
US-7834002-B2 4-amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-07-31 US disclosed
EP-1740574-B1 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2007-06-27 EP disclosed
EP-1740574-A2 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES Otsuka Pharmaceutical Company, Limited (JP) 2007-01-10 EP disclosed
WO-2005105778-A2 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives ADORA2A, ADORA1, ADORA3 CYP1A2 497/4885CYP3A4 885/4885CYP2D6 1784/4885
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives ADORA2A, ADORA1, ADORA3 CYP1A2 497/4885CYP3A4 885/4885CYP2D6 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.